XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Summary of Cash, Cash Equivalents and Short-Term Investments

The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as a long-term restricted cash on the condensed consolidated balance sheet as of September 30, 2024.

		September 30, 2024				December 31, 2023
Cash, cash equivalents, and restricted cash
Cash		$	850,544			$	1,231,871
Money market funds			5,772,131				4,893,387
Commercial paper			—				746,048
Restricted Cash			375,000				—
		$	6,997,675			$	6,871,306
Short-term investments
US government agency debt securities		$	—			$	1,497,099
Commercial paper			—				497,563
		$	—			$	1,994,662

Summary of Revenue by Major Source

The following table presents revenue by major source:

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2024				2023				2024				2023
Direct to patient		$	7,431,751			$	3,501,958			$	15,491,584			$	9,245,345
Clinical/Medical providers			1,775,835				1,527,565			$	4,991,158			$	3,474,510
License revenue			—				50,000				—				1,764,920
Total revenue from contracts with customers		$	9,207,586			$	5,079,523			$	20,482,742			$	14,484,775

Summary of Potential Common Shares Issuable

Potential dilutive common shares issuable consist of the following at:

		September 30,
		2024				2023
Stock options			23,246				24,982
Restricted stock units			1,234,357				1,621,935
Other warrants			668,250				668,250
Total			1,925,853				2,315,167

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of cash, cash equivalents, and investments.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration